🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

27 results for “vortioxetine” Clear

  1. ATOMOXETINE , PAROXETINE , MIANSERIN , VORTIOXETINE , VENLAFAXINE , DESVENLAFAXINE , KETAMINE , CLOMIPRAMINE , DULOXETINE , DOSULEPIN , IMIPRAMINE , AMITRIPTYLINE , ESCITALOPRAM , NORTRIPTYLINE , MILNACIPRAN , SERTRALINE , ESKETAMINE , FLUVOXAMINE , REBOXETINE , FLUOXETINE , TRAZODONE , CITALOPRAM , BUPROPION , AGOMELATINE , MIRTAZAPINE , ESKETAMINE , TIANEPTINE

    Disc Medicine

    Major depressive disorder

    phase 3 small molecule active

    1 trial

  2. Vortioxetine

    Takeda Pharmaceuticals International AG

    Generalized Anxiety Disorder

    phase 3 small molecule completed

    3 trials

  3. Vortioxetine

    Takeda Pharmaceuticals International AG

    TBI

    phase 3 small molecule terminated

    1 trial

  4. Vortioxetine

    Takeda Pharmaceuticals International AG

    Treatment Outcome

    phase 3 small molecule completed

    1 trial

  5. Vortioxetine

    COGNITION THERAPEUTICS INC

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  6. Vortioxetine

    Takeda Pharmaceuticals International AG

    Depressive Disorder, Major

    phase 3 small molecule completed

    5 trials

  7. Vortioxetine 10 mg/day

    Takeda Pharmaceuticals International AG

    Depressive Disorder, Major

    phase 3 small molecule completed

    2 trials

  8. Vortioxetine tablets

    Takeda Pharmaceuticals International AG

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  9. Vortioxetine

    Takeda Pharmaceuticals International AG

    Binge Eating Disorder

    phase 2 small molecule completed

    1 trial

  10. Vortioxetine

    COGNITION THERAPEUTICS INC

    Post-COVID-19 Condition

    phase 2 small molecule completed

    1 trial

  11. Vortioxetine (IV)

    Takeda Pharmaceuticals International AG

    Depressive Disorder, Major

    phase 2 small molecule completed

    1 trial

  12. vortioxetine (Lu AA21004)

    Takeda Pharmaceuticals International AG

    Depressive Disorder, Major

    phase 2 small molecule completed

    1 trial

  13. Bioequivalence clinical trial of two formulations of vortioxetine.

    Laboratorios Tillomed Spain S.L.U

    Healthy volunteers

    phase 1 other active

    1 trial

  14. Bioequivalence of Vortioxetine 20 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions

    Laboratorios Tillomed Spain S.L.U

    No medical condition

    phase 1 other active

    1 trial

  15. Bioequivalence of Vortioxetine 5 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions.

    Laboratorios Tillomed Spain S.L.U

    No medical condition.

    phase 1 other active

    1 trial

  16. Randomised, crossover bioequivalence clinical trial of vortioxetine 20 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions.

    Laboratorios Tillomed Spain S.L.U

    Antidepressant

    phase 1 other active

    1 trial

  17. Vortioxetine

    Takeda Pharmaceuticals International AG

    Severe Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  18. Vortioxetine

    Takeda Pharmaceuticals International AG

    Healthy Adult Participants

    phase 1 small molecule completed

    1 trial

  19. Vortioxetine

    Takeda Pharmaceuticals International AG

    Healthy

    phase 1 small molecule completed

    1 trial

  20. Vortioxetine

    Takeda Pharmaceuticals International AG

    Type2 Diabetes

    approved small molecule terminated

    1 trial

  21. Vortioxetine

    Takeda Pharmaceuticals International AG

    Unipolar Major Depression

    approved small molecule terminated

    1 trial

  22. Vortioxetine

    Takeda Pharmaceuticals International AG

    Depressive Disorder

    approved small molecule terminated

    1 trial

  23. Vortioxetine

    Takeda Pharmaceuticals International AG

    Major Depressive Disorder

    approved small molecule completed

    9 trials

  24. Vortioxetine

    Takeda Pharmaceuticals International AG

    Schizophrenia

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources